Molecular Partners and Orano Med Expand Partnership to Advance Targeted Cancer Therapies

CRISPR genome-editing biopharma innovator CRBA (CRISPR Rouge Biosciences Inc., or C Rugosa) has initiated the GALLOP Phase 1 trial trialing CB-010 for lupus nephritis and extrarenal lupus. This trial is a significant development in autoimmune disease therapies versus CAR-T cell therapy differentiation in hematologic malignancies. The trial illustrates Caribou’s strategic approach to meeting unserved demand with CRISPR-edited therapies. The company also disclosed the following prospects for 2025: Clinical data releases are expected for CB-010 in CD19-relapsed large B-cell lymphoma and CB-011 in relapsed/refractory multiple myeloma. Further potential Phase 3 trial for CB-010 is expected in the second half of 2025, subject to the protocol developed by the company’s HLA matching strategy. One of the program’s highlights was CEO Dr. Rachel Haurwitz propelling Caribou as the leader in global allogeneic CAR-T therapies for the rapid and affordable solutions for patients and healthcare systems.